The global Urokinase Solution market size is predicted to grow from US$ 7.23 million in 2025 to US$ 10.40 million in 2032; it is expected to grow at a CAGR of 5.3% from 2026 to 2032.

Urokinase Solution is a clot-dissolving medicine. It is a natural enzyme (a protein) that activates the body?s own fibrinolytic system by converting plasminogen into plasmin, and plasmin then breaks down fibrin, which is the ?mesh? that holds a blood clot together. This is why urokinase is called a thrombolytic or ?clot-buster.? The market for urokinase mainly includes injectable products (usually a sterile powder that is dissolved before use) that are given in hospitals, either through a vein or through a catheter directly to the clot area, depending on the indication and local practice. The clinical risk that shapes this market is also simple: because the drug dissolves clots, it can also weaken normal clotting at injury sites, so bleeding is the key safety concern and a major reason urokinase is used in controlled hospital settings.

In 2025, global Urokinase Solution production reached approximately 254.8 BIU, with an average global market price of around US$ 29 per MIU. The global single-line production capacity ranges from 10 to 15 BIU per year. The industrys gross profit margin is approximately 25%-35%.

United States market for Urokinase Solution is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Urokinase Solution is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Urokinase Solution is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Urokinase Solution players cover Syner-Med, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

Infinity Market Research newest research report, the ?Urokinase Solution Industry Forecast? looks at past sales and reviews total world Urokinase Solution sales in 2025, providing a comprehensive analysis by region and market sector of projected Urokinase Solution sales for 2026 through 2032. With Urokinase Solution sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Urokinase Solution industry.

This Insight Report provides a comprehensive analysis of the global Urokinase Solution landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Urokinase Solution portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Urokinase Solution market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Urokinase Solution and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Urokinase Solution.

This report presents a comprehensive overview, market shares, and growth opportunities of Urokinase Solution market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Source of Human Urine
    Reorganization of Technical Production
    Segmentation by Clinical Use:
    Pulmonary Embolism Thrombolysis
    Deep Vein Thrombosis
    Peripheral Arterial Occlusion Thrombolysis
    Catheter / Cannula Occlusion Clearance
    Others
    Segmentation by Administration Approach:
    Systemic Infusion
    Catheter-directed Thrombolysis (CDT)
    Intracatheter Dwell / Lock Technique
    Segmentation by Purity:
    Standard Clinical Grade
    High-purity / Low-impurity Grade
    Low Endotoxin / Low Bioburden Specifications

Segmentation by Application:

    Hospital
    Clinic
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Syner-Med
    Wanhua Biochem
    Jiangxi Haoran Bio-Pharma
    Jiangsu Aidea Pharmaceutical
    Techpool
    Microbic Biosystems
    LIVZON
    Wuhan Humanwell Pharma
    Tianjin Biochem Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Urokinase Solution market?
What factors are driving Urokinase Solution market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Urokinase Solution market opportunities vary by end market size?
How does Urokinase Solution break out by Type, by Application?